Oxurion

Oxurion NV is a biopharmaceutical company headquartered in Belgium. The company is dedicated to developing vision-preserving treatments for patients suffering from diseases that affect the back of the eye. It has developed a portfolio of drug candidates for the treatment of various conditions, including diabetic eye disease, which is the leading cause of blindness among working-age populations worldwide. It holds global rights to Jetrea (ocriplasmin), a pharmacological vitreolysis agent approved for the treatment of symptomatic vitreomacular adhesion (in the U.S.) and vitreoretinal traction (outside the U.S.).